These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22324936)

  • 1. Innate immune dysfunction in inflammatory bowel disease.
    Gersemann M; Wehkamp J; Stange EF
    J Intern Med; 2012 May; 271(5):421-8. PubMed ID: 22324936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defensins and inflammation: the role of defensins in inflammatory bowel disease.
    Ramasundara M; Leach ST; Lemberg DA; Day AS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):202-8. PubMed ID: 19215333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defensin-immunology in inflammatory bowel disease.
    Wehkamp J; Stange EF; Fellermann K
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S137-44. PubMed ID: 20117337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paneth cell defensins: key effector molecules of innate immunity.
    Bevins CL
    Biochem Soc Trans; 2006 Apr; 34(Pt 2):263-6. PubMed ID: 16545089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From intestinal stem cells to inflammatory bowel diseases.
    Gersemann M; Stange EF; Wehkamp J
    World J Gastroenterol; 2011 Jul; 17(27):3198-203. PubMed ID: 21912468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome.
    Langhorst J; Junge A; Rueffer A; Wehkamp J; Foell D; Michalsen A; Musial F; Dobos GJ
    Am J Gastroenterol; 2009 Feb; 104(2):404-10. PubMed ID: 19174795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
    Sartor RB
    Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis.
    Gersemann M; Becker S; Kübler I; Koslowski M; Wang G; Herrlinger KR; Griger J; Fritz P; Fellermann K; Schwab M; Wehkamp J; Stange EF
    Differentiation; 2009 Jan; 77(1):84-94. PubMed ID: 19281767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paneth cells and the innate immune response.
    Wehkamp J; Stange EF
    Curr Opin Gastroenterol; 2006 Nov; 22(6):644-50. PubMed ID: 17053443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crohn's disease--defect in innate defence.
    Gersemann M; Wehkamp J; Fellermann K; Stange EF
    World J Gastroenterol; 2008 Sep; 14(36):5499-503. PubMed ID: 18810765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
    Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease.
    Strugala V; Dettmar PW; Pearson JP
    Int J Clin Pract; 2008 May; 62(5):762-9. PubMed ID: 18194279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defensins and other antimicrobial peptides in inflammatory bowel disease.
    Wehkamp J; Schmid M; Stange EF
    Curr Opin Gastroenterol; 2007 Jul; 23(4):370-8. PubMed ID: 17545771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Events at the host-microbial interface of the gastrointestinal tract. V. Paneth cell alpha-defensins in intestinal host defense.
    Bevins CL
    Am J Physiol Gastrointest Liver Physiol; 2005 Aug; 289(2):G173-6. PubMed ID: 16014978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa.
    Salzman NH; Underwood MA; Bevins CL
    Semin Immunol; 2007 Apr; 19(2):70-83. PubMed ID: 17485224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging immunological targets in inflammatory bowel disease.
    Monteleone G; Pallone F; MacDonald TT
    Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn's disease.
    Kübler I; Koslowski MJ; Gersemann M; Fellermann K; Beisner J; Becker S; Rothfuss K; Herrlinger KR; Stange EF; Wehkamp J
    Aliment Pharmacol Ther; 2009 Sep; 30(6):621-33. PubMed ID: 19549264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal innate immune cells regulate both gut homeostasis and intestinal inflammation.
    Kurashima Y; Goto Y; Kiyono H
    Eur J Immunol; 2013 Dec; 43(12):3108-15. PubMed ID: 24414823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins.
    Wehkamp J; Schwind B; Herrlinger KR; Baxmann S; Schmidt K; Duchrow M; Wohlschläger C; Feller AC; Stange EF; Fellermann K
    Dig Dis Sci; 2002 Jun; 47(6):1349-55. PubMed ID: 12064812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory bowel disease: an impaired barrier disease.
    Jäger S; Stange EF; Wehkamp J
    Langenbecks Arch Surg; 2013 Jan; 398(1):1-12. PubMed ID: 23160753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.